Approval of proposal involving pegfilgrastim and tocilizumab
PHARMAC is pleased to announce the approval of a proposal to list pegfilgrastim (Neulastim) for prevention of neutropenia in patients undergoing cancer chemotherapy and tocilizumab (Actemra) for systemic juvenile idiopathic arthritis, from 1 July 2013, through an agreement with Roche Products (NZ) Limited.
This was the subject of a consultation letter dated 12 April 2013.